BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommends the use of forced expiratory volume in 1s (FEV1) to assess airways …

The aim of this double-blind, double-dummy, crossover, randomised, pilot study was to
explore the acute effects of adding salmeterol and tiotropium in patients with stable COPD. A …

Background and objective: The effects of tiotropium, a long‐acting anticholinergic drug, were
compared with those of the combination of salmeterol, a long‐acting β2‐agonist, and …

Background The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol
(VI) 100/25 μg combination has been demonstrated numerically, but not statistically …

The degree of acute improvement in spirometric indices after bronchodilator inhalation
varies among chronic obstructive pulmonary disease (COPD) patients, and depends upon …

Background and objective Combination long‐acting β2‐agonist/long‐acting muscarinic
antagonist (LABA/LAMA) has demonstrated superior clinical outcomes over LABA/inhaled …

Study objective To examine the effect of fluticasone propionate, 250 μg/salmeterol, 50 μg
combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of …

Although long-acting inhaled β2-agonists improve various outcome measures in COPD, no
double-blind study has yet shown a significant effect of these drugs on exercise capacity. In …

We explored the additive effect of titrated oral theophylline in patients with stable chronic
obstructive pulmonary disease (COPD) who received both tiotropium, 18μg od, and …

Background AMPLIFY assessed the efficacy and safety of aclidinium bromide/formoterol
fumarate (AB/FF) vs its monocomponents and tiotropium (TIO) in patients with moderate-to …